Press Releases

Promore Pharma granted US patent regarding treatment of chronic wounds

Interim report January – September 2021

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2021

Nomination Committee Appointed for the Annual General Meeting 2022 in Promore Pharma

Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention

Promore Pharma announces that scientific article has been published on clinical study results with ropocamptide for venous leg ulcers

Promore Pharma receives delivery of hyaluronic acid from Italian manufacturer Fidia

Interim report January – June 2021

Invitation to Conference Call regarding Promore Pharma’s Q2 Report 2021

The rights issue is registered and the trading in Paid Subscription Shares ceases

Outcome in Promore Pharma’s rights issue

Promore Pharma publishes prospectus

Promore Pharma informs about the last day of trading to receive subscription rights

Interim report January – March 2021

Report from an extra General Meeting of Promore Pharma AB held on 27 May 2021

Report from the Annual General Meeting of Promore Pharma AB held on 27 May 2021

Promore Pharma participates in “Småbolagsdagarna 2021”, an event organized by Aktiespararna

Invitation to Conference Call regarding Promore Pharma’s Q1 Report 2021

Promore Pharma is granted a US patent regarding skin scarring

Notice of Extraordinary General Meeting in Promore Pharma AB (publ)

Promore Pharma AB intends to carry out a fully secured rights issue in order to implement the new strategy

Promore Pharma’s Annual Report 2020 and AGM related Documents Published

Promore Pharma signs agreement on production of hyaluronic acid with Italian manufacturer Fidia

NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL)

Promore Pharma comments on media reports about ensereptide

Promore Pharma deregisters warrants

Promore Pharma updates its strategy and focuses on scar prevention

Year-end report 2020

Invitation to Presentation of Promore Pharma’s Year-end report for 2020

Promore Pharma changes Certified Adviser to Erik Penser Bank AB